Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download 4.1 MB pdf)
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce